Dr. Reddy's Q4 preview: Strong sales, margin pressure

Dr. Reddy's Laboratories is set to announce its Q4 FY25 earnings on May 9, 2025. Market analysts expect a solid performance backed by strategic acquisitions, strong execution across key markets, and contributions from new business verticals. Revenue Outlook The company's consolidated revenue is projected to rise approximately 15.5 per cent year-on-year (YoY) to around ₹7,020 crore. This strong growth is primarily driven by the integration of the Haleon over-the-counter (OTC) business and steady traction from the generic version of Revlimid (gRevlimid), which alone is expected to contribute about $160 million in quarterly sales. Profit Expectations Net profit is estimated to increase by 14.95 per cent YoY, reaching around ₹1,022 crore. This gro